United States · Biopharma startup

Kura Oncology

Kura Oncology, a biopharmaceutical company, advances a pipeline of precision medicines for the treatment of solid tumors and blood cancers.

Funding reportedLast round: Post ipo equity

BiopharmaLa Jolla, United States

What company datasets say Kura Oncology raised

Funding, as reported

Reported in all$1.2Bin dollars
Rounds12
Last roundPost ipo equity
Last round dateJan 2024
Investors listed12
SEC Form D$242M sold, 2 filings, last Feb 2024

Founders and team

From Kura Oncology's own website and the SEC filings it signed: 13 on the team.

  • Jennifer FulkChief Financial Officer
  • Brian PowlChief Commercial Officer
  • Kathleen FordChief Operating Officer
  • Carol SchaferSeptember 21, 2022 / in Board of Directors
  • Diane ParksSeptember 21, 2022 / in Board of Directors
  • Faheem HasnainSeptember 21, 2022 / in Board of Directors
  • Mary SzelaSeptember 21, 2022 / in Board of Directors
  • Stephen DaleExecutive Officeri
  • Teresa BairExecutive Officeri
  • Thomas MalleySeptember 21, 2022 / in Board of Directors
  • Troy WilsonExecutive Officer, Directori
  • Samir VattompadamTeam
  • Tom DoyleTeam

On the board, as filediHelen Collins

On 4 portfolio pages

Investors who name them

Each firm lists Kura Oncology on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.

Biopharma in United States

Startups like it

Is this your company?

Add your raise, your deck and your story, and put Kura Oncology in front of investors. Or tell us what we have wrong.

List your startupSend a correction